Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Xilio Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 28
- 0 vs. Q3 2022
- Shares held
- 15.9M
- −12.9K (−0.1%) vs. Q3 2022
- Total value
- $42.8M
- −$3.54M (−7.6%) vs. Q3 2022
- New holders
- 2
- 7 more added
- Sold out
- 2
- 5 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $7.55M | 0.84% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $7.42M | 0.89% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 2,425,000 | $6.52M | 1.02% | 00.0% | Unchanged |
| FMR LLC | 1,907,671 | $5.13M | 0.00% | −312,091−14.1% | Reduced |
| RiverVest Venture Management LLC | 1,441,444 | $3.88M | 4.52% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 1,362,878 | $3.67M | 0.09% | 00.0% | Unchanged |
| Vanguard Group Inc | 890,353 | $2.40M | 0.00% | −1,180−0.1% | Reduced |
| Artal Group S.A. | 450,000 | $1.21M | 0.07% | 00.0% | Unchanged |
| Harvard Management Co Inc | 416,059 | $1.12M | 0.14% | 00.0% | Unchanged |
| Trustees of Columbia University in the City of New York | 249,635 | $672.0K | 1.39% | +249,635 | New |
| Bank of America Corp | 233,068 | $627.0K | 0.00% | +233,068 | New |
| Soleus Capital Management, L.P. | 226,941 | $610.5K | 0.09% | −226,719−50.0% | Reduced |
| FIL Ltd | 218,705 | $588.3K | 0.00% | 00.0% | Unchanged |
| Laurion Capital Management LP | 142,900 | $384.4K | 0.01% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 110,481 | $297.2K | 0.01% | +34,400+45.2% | Added |
| Geode Capital Management, LLC | 84,726 | $227.0K | 0.00% | +1,137+1.4% | Added |
| BlackRock Inc. | 49,439 | $133.0K | 0.00% | +3,081+6.6% | Added |
| Renaissance Technologies LLC | 37,100 | $100.0K | 0.00% | +8,600+30.2% | Added |
| Millennium Management LLC | 26,892 | $72.0K | 0.00% | −739−2.7% | Reduced |
| Morgan Stanley | 25,611 | $68.9K | 0.00% | +18,771+274.4% | Added |
| Cannell Capital LLC | 17,025 | $45.8K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 15,690 | $42.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 12,900 | $34.7K | 0.00% | 00.0% | Unchanged |
| Nwam LLC | 10,000 | $26.9K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,259 | $11.0K | 0.00% | +2,190+105.8% | Added |
| JPMorgan Chase & Co | 2,701 | $7.00K | 0.00% | −3−0.1% | Reduced |
| UBS Group AG | 201 | $541 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 77 | $207 | 0.00% | +2+2.7% | Added |
| Ergoteles LLC | 0 | $0 | 0.00% | −12,941−100.0% | Sold out |
| RBF Capital, LLC | 0 | $0 | 0.00% | −10,072−100.0% | Sold out |
| AJU IB Investment Co., Ltd. | – | – | – | – | Not filed |